RESULTS ROUND-UP: Covidien growing faster than JnJ; BCR, DGX
This article was originally published in Clinica
Executive Summary
Covidien, soon to be part of Medtronic, had a mixed third quarter with “light” organic sales growth, but an improvement in profitability, noted Morgan Stanley analyst David Lewis. The firm’s revenues climbed 4% to $2.69bn, but organic growth of 3% “modestly missed” Mr Lewis’s estimate of 4%. More positively, adjusted diluted earnings-per-share of $1.04 were 14% up over last year’s Q2, in line with the analyst’s (and company’s) previous prediction of double-digit EPS growth.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.